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Bleomycin is an effective drug used in the therapy of many malignant diseases. Such tox-
icities as fever, chills, and pulmonary fibrosis are well known to occur following administra-
tion of this drug. A rare fatal hyperpyrexial response has also been noted with this agent. We
describe a case of fatal hyperthermia after an injection of bleomycin. Unlike earlier reported
cases, our patient developed her reaction following prior uneventful therapy with bleomycin
rather than as a response to initial treatment. Factors that may be related to the hyperpyrexial
response to bleomycin are discussed and the relevant literature reviewed.
Bleomycin is an effective anti-tumor agent often used in the therapy of testicular
carcinoma, lymphoma, and lung cancer. Several toxic reactions have been reported
with this drug, including fever, chills, nausea, vomiting, and pulmonary fibrosis. An
uncommon fatal hyperpyrexial response to this agent has also been observed
[4,6,7,8]. This fulminant hyperthermia reaction has usually been noted following
the initial administration of bleomycin. We report an unusual case of this hyper-
pyrexial response in a lymphoma patient treated with bleomycin several weeks after
prior administration of this drug.
CASE REPORT
A 50-year-oldwhitefemalewas evaluated for fevers, sweats, and lymphadenopathy.
A cervical lymph node biopsy revealed a diffuse histiocytic lymphoma. Staging with
a CAT scan, gallium scan, and bone marrow biopsy was consistent with Stage IIIB
disease. The patient was treated with cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) with significant improvement. Prior to the next course of
chemotherapy the patient experienced fevers, sweats, and adenopathy. Therapy was
initiated with bleomycin and vincristine because of persisting neutropenia. The pa-
tient received a test dose of bleomycin subcutaneously without reaction. Subse-
quently, she received 9 mg of bleomycin intravenously and experienced chills and
fever two hours later. The patient responded to therapy with acetaminophen and
Benadryl. The patient's symptoms resolved and she was subsequently treated with
CHOP and discharged.
A week later, the patient again developed fever and chills. Her leucocyte count
was 800 with 10 percent neutrophils. Cultures were obtained and antibiotics given.
All cultures were negative at four days and she remained febrile despite antibiotic
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All rights of reproduction in any form reserved.therapy. For this reason, bleomycin and vincristine were again administered. Prior
to her bleomycin injection, the patient was pre-treated with Benadryl and
acetaminophen. Two hours following her bleomycin therapy, the patient developed
severe rigors, a temperature of 107.50 rectally, and rapidly lost consciousness. On
examination, she was noted to be hypotensive, tachycardic, and tachypneic. Follow-
ing intubation, the patient received externally applied ice packs, saline, Benadryl,
epinephrine, Solumedrol, and acetaminophen with normalization of her temperature
within two hours. After her initial resuscitation, the patient developed disseminated
intravascular coagulation, renal failure, hepatic failure, and cardiovascular collapse.
Despite intensive therapy with antibiotics, heparin, steroids, transfusions, and
hemodynamic support, the patient died within 48 hours. All subsequent cultures
were negative. Permission for a postmortem examination was refused.
DISCUSSION
Fever following bleomycin therapy is relatively common, occurring in approx-
imately 20-53 percent of patients [1,2,31. This febrile reaction may be less frequent
with lower doses of drug and tends to abate with subsequent treatment [1,4]. The
onset of fever is usually within two to six hours of drug administration and is often
associated with chills. The patient's temperature may remain elevated for several
hours [1]. The role of therapy in preventing this toxicity has not been proven.
The mechanism of bleomycin hyperpyrexia in man is uncertain. Initially, it was
thought to be a consequence of endotoxin contamination of bleomycin prepara-
tions. Dinarello et al. [5], however, demonstrated that the febrile reaction due to
bleomycin appeared unrelated to contaminating bacterial endotoxin. Rather, they
proposed that the drug results in the release of an endogenous pyrogen. The exact
source and action of this pyrogen remain unknown.
A number of cases of fulminant hyperthermia have been reported. Blum et al. [41
observed four deaths and six sublethal reactions in 808 patients receiving this drug.
They noted that 6 percent of lymphoma patients experienced this response. Levy [6]
Ma [7], and Durbin [8] have described extreme hyperpyrexial responses occurring in
patients receiving 7.5 mg, 6 mg, and 1 mg of bleomycin as test doses. The clinical
picture observed with bleomycin-induced hyperthermia in many reports is similar to
that ofour patient. In most cases, several hours after bleomycin therapyhigh fevers,
hypotension, and cardiopulmonary collapse occur. Despite intensive therapy and
hemodynamic support most patients die.
In many of the previously reported cases, this hyperthermic response was noted as
occurring with the initial injection of the drug. In our case, the reaction occurred
following prior therapy with bleomycin. Moreover, these injections were several
weeks apart with the usual toxic reactions noted following the first treatment. In ad-
dition, prior to her fatal response, this patient was pre-treated with acetaminophen
and Benadryl. Our patient did receive intravenous bleomycin. Mosher et al. [3] have
reported a decreased frequency of toxicity with intra-muscular as compared to in-
travenous injections of bleomycin. Whether the route of administration is of
significance in the development of this fulminant hyperthermic response is difficult
to ascertain.
It is of interest to speculate upon the possible role of endogenous pyrogen as a
mediator of this reaction. Conceivably, tumor lysis and release of pyrogens may be
responsible for the initiation of this reaction. Of importance in this regard may be
lymphomas or tumors associated with fever in which endogenous pyrogens may play
a role. Although rare, perhaps such patients should be monitored closely for
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bleomycin-induced hyperthermia. The role of steroids, Benadryl, and antipyretics in
preventing this problem is uncertain, although they should be considered as pre-
treatment in such cases.
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